- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,926 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 230
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Neoplasms
- Interventions
- palbociclib plus fulvestrant, fulvestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 95,637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
- Interventions
- RLY-2608, Fulvestrant, Palbociclib 125mg, Ribociclib 400mg, Ribociclib 600mg, PF-07220060 100mg, PF-07220060 300 mg
- Drug
- Lead sponsor
- Relay Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer
- Interventions
- Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Springdale, Arkansas + 30 more
- Conditions
- Malignant Neoplasms of Female Genital Organs
- Interventions
- Fulvestrant, Abemaciclib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
- Interventions
- Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 55
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
- Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
- Interventions
- Palbociclib, Tamoxifen
- Drug
- Lead sponsor
- Oana Danciu, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Lansing, Michigan • Minneapolis, Minnesota + 4 more
- Conditions
- HR+/HER2-negative Breast Cancer
- Interventions
- TOS-358, Fulvestrant, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- Totus Medicines
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma
- Interventions
- Belzutifan, Palbociclib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Metastatic Urothelial Carcinoma (UC)
- Interventions
- Palbociclib
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib + aromatase inhibitor, Aromatase inhibitor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
- Interventions
- Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Kansas City, Missouri + 2 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Fulvestrant, Tamoxifen, Palbociclib
- Drug
- Lead sponsor
- Shannon Puhalla
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Recurrent Mantle Cell Lymphoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
- Drug
- Lead sponsor
- LeonaBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 36
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Santa Rosa, California + 25 more
- Conditions
- Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Fulvestrant, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 7
- States / cities
- Corona, California • Duarte, California • Lancaster, California + 4 more
- Conditions
- Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
- Interventions
- Everolimus, Neratinib, Palbociclib, Trametinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
- Interventions
- Palbociclib Oral Capsule, Intrathecal Triple Therapy, Dexamethasone, Bortezomib, Dasatinib, Doxorubicin, Ruxolitinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Breast Cancer, Solid Tumor
- Interventions
- Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee
- Conditions
- Breast Cancer, Solid Tumor, Adult
- Interventions
- APG-2575, Palbociclib
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Austin, Texas • Houston, Texas + 1 more
- Conditions
- Ovarian Cancer
- Interventions
- Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
- Conditions
- Solid Tumors
- Interventions
- INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 18
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 13 more
- Conditions
- Female Breast Carcinoma, Breast Cancer
- Interventions
- anastrozole, Palbociclib
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina